litlas
Log inCreate account

Binghe Xu

Active 1987–2025

191
Papers
31,531
Citations
74
h-index
181
i10-index

Citations

Citations per year for Binghe Xu1971: 1 citations1982: 1 citations1991: 1 citations1993: 3 citations1994: 1 citations1996: 1 citations1997: 4 citations1999: 3 citations2000: 1 citations2001: 3 citations2002: 4 citations2003: 7 citations2004: 1 citations2005: 1 citations2006: 2 citations2007: 3 citations2008: 14 citations2009: 19 citations2010: 21 citations2011: 22 citations2012: 17 citations2013: 22 citations2014: 43 citations2015: 102 citations2016: 153 citations2017: 157 citations2018: 220 citations2019: 838 citations2020: 1,119 citations2021: 1,249 citations2022: 1,436 citations2023: 1,538 citations2024: 2,429 citations2025: 1,374 citations2026: 39 citations1972–1981: no citations, so these years are not shown1983–1990: no citations, so these years are not shown1992: no citations, so this year is not shown1995: no citations, so this year is not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,743 citing papers, 18.5% of this breakdownChina: 2,357 citing papers, 15.9% of this breakdownItaly: 1,049 citing papers, 7.1% of this breakdownUnited Kingdom: 725 citing papers, 4.9% of this breakdownGermany: 670 citing papers, 4.5% of this breakdownFrance: 641 citing papers, 4.3% of this breakdownSpain: 607 citing papers, 4.1% of this breakdownJapan: 426 citing papers, 2.9% of this breakdownCanada: 399 citing papers, 2.7% of this breakdownSwitzerland: 393 citing papers, 2.6% of this breakdownBelgium: 391 citing papers, 2.6% of this breakdownAustralia: 366 citing papers, 2.5% of this breakdown
0%18.5%Other 27.4%

Institutions

Fields

  • Medicine60.4%
  • Biochemistry, Genetics and Molecular Biology31.2%
  • Immunology and Microbiology2.7%
  • Computer Science1.6%
  • Engineering1%
  • Materials Science0.9%
  • Other2.2%

Topics

  • HER2/EGFR in Cancer Research8.4%
  • Breast Cancer Treatment Studies7.9%
  • Advanced Breast Cancer Therapies7%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Cancer Treatment and Pharmacology3.4%
  • PARP inhibition in cancer therapy3.4%
  • Other65.8%

Coauthors

All papers

Open in search
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

    Authors: Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron - New England Journal of Medicine 2022 cited by 2,548

  2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Authors: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, PierFranco Conte - New England Journal of Medicine 2017 cited by 3,214

  3. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    Authors: Javier Cortés, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Chiun-Sheng Huang, Jee Hyun Kim, Joanne W.Y. Chiu, Jose Luiz Pedrini, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz - New England Journal of Medicine 2022 cited by 1,124

  4. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

    Authors: Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu, Fei Ma, Zemin Zhang, Zhihua Liu - Cancer Cell 2021 cited by 786

  5. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    Authors: Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés - The Lancet 2022 cited by 642

  6. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Authors: Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus, Giuseppe Curigliano, Matti Aapro, Fabrice André, C.H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Frances Boyle, Maria João Cardoso, L.A. Carey, Javier Cortés, Nagi S. El Saghir, Mona Elzayat, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Karen A. Gelmon, Joseph Gligorov, Renate Haidinger, Nadia Harbeck, Xin Hu, Bella Kaufman, Rajneesh Kaur, Belinda E. Kiely, S.-B. Kim, NU Lin, Shirley Mertz, Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, A. Prat, Frédérique Penault‐Llorca, Hope S. Rugo, G. W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer - Annals of Oncology 2020 cited by 1,356

  7. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    Authors: Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer - Annals of Oncology 2016 cited by 2,062

  8. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Authors: Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, William P. Weber, Philip Poortmans, Meredith M. Regan, H.-J. Senn, Eric P. Winer, Michael Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel Morales, Sara Y. Brucker, Harold J. Burstein, David Cameron, Fátima Cardoso, Lisa A. Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence A. Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 cited by 803

  9. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  10. Breast cancer: an up‐to‐date review and future perspectives

    Authors: Ruoxi Hong, Binghe Xu - Cancer Communications 2022 cited by 372

  11. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: Mark E. Robson, Nadine Tung, PierFranco Conte, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek - Annals of Oncology 2019 cited by 760

  12. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    Authors: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 cited by 357

  13. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    Authors: Alan S. Coates, Eric P. Winer, Aron Goldhirsch, Richard D. Gelber, Michael Gnant, Martine Piccart, Beat Thürlimann, H.-J. Senn, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Viviana Galimberti, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Jens Huober, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C. Kent Osborne, Ann H. Partridge, Lorena de la Peña, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gϋnter von Minckwitz, Toru Watanabe, Timothy J. Whelan, Eric P. Winer, Binghe Xu - Annals of Oncology 2015 cited by 1,837

  14. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

    Authors: Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wěi Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou - The Lancet Oncology 2021 cited by 393

  15. Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling

    Authors: Cong Li, Shi Qiu, Xiaohan Liu, Fengzhu Guo, Jingtong Zhai, Zhijun Li, Linghui Deng, Liming Ge, Haili Qian, Lu Yang, Binghe Xu - Signal Transduction and Targeted Therapy 2023 cited by 143

  16. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Authors: Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer, Michael Gnant, Peter Dubsky, Sibylle Loibl, Marco Colleoni, Meredith M. Regan, Martine Piccart, Hans-Jörg Senn, Beat Thürlimann, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Sara Y. Brucker, Fátima Cardoso, Lisa A. Carey, Eva Ciruelos, Jack Cuzick, Carsten Denkert, Angelo Di Leo, Bent Ejlertsen, Prudence A. Francis, V.E. Galimberti, Judy E. Garber, Bahadır M. Güllüoğlu, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Chiun‐Sheng Huang, Jens Huober, Hussein Khaled, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, Kent C. Osborne, Olivia Pagani, Ann H. Partridge, K. Pritchard, Jungsil Ro, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Toru Watanabe, Timothy J. Whelan, Binghe Xu - Annals of Oncology 2017 cited by 1,255

  17. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Authors: Richard J. Gray, Rosie Bradley, Jeremy Braybrooke, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, William E. Barlow, Judith M. Bliss, Paolo Bruzzi, David Cameron, George Fountzilas, Sibylle Loibl, John R. Mackey, Miguel Martín, Lucia Del Mastro, Volker Möbus, Valentina Nekljudova, Sabino De Placido, Sandra M. Swain, Michael Untch, Kathleen I. Pritchard, Jonas Bergh, Larry Norton, Clare Boddington, Julie Ann Burrett, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Lucy Gettins, Jon Godwin, Robert K. Hills, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Yaochen Wang, Zhe Wang, Peter A. Fasching, Nadia Harbeck, Pascal Piedbois, Michael Gnant, Guenther G. Steger, Angelo Di Leo, Stella Dolci, Prue Francis, Denis Larsimont, J.-M. Nogaret, C. Philippson, Martine Piccart, Sabine C. Linn, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen, S.B. Vliek, John R. Mackey, Dennis Slamon, John M.S. Bartlett, Vivien Bramwell, Bingshu E. Chen, Stephen Chia, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Joseph L. Pater, Eileen Rakovitch, Lois E. Shepherd, Dongsheng Tu, Timothy J. Whelan, Donald A. Berry, Gloria Broadwater, Constance Cirrincione, Hyman B. Muss, Raymond L. Weiss, Yi Shan, Yong fu Shao, Xiang Wang, Binghe Xu, Dongbing Zhao, Harry Bartelink, Nina Bijker, Jan Bogaerts, Fátima Cardoso, Tanja Čufer, Jean‐Pierre Julien, Philip Poortmans, Emiel J. Rutgers, Cornelis J.�H. van de Velde, Eva Carrasco, Miguel Ángel Seguí, Jens‐Uwe Blohmer, Serban Dan Costa, Bernd Gerber and 67 more - The Lancet 2019 cited by 394

  18. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

    Authors: Dennis J. Slamon, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, Fran Visco, Rodrigo Fresco, Tetiana Taran, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2023 cited by 139

  19. Targeted therapeutic options and future perspectives for HER2-positive breast cancer

    Authors: Jiani Wang, Binghe Xu - Signal Transduction and Targeted Therapy 2019 cited by 408

  20. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    Authors: Fátima Cardoso, Shani Paluch–Shimon, Eva Schumacher-Wulf, Leonor Vasconcelos de Matos, Karen A. Gelmon, Matti Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chávez‐MacGregor, Runcie C.W. Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda E. Kiely, Sungbae Kim, Smruti Koppikar, Marion Kuper‐Hommel, Frédéric Lecouvet, Ginny Mason, Shirley Mertz, Volkmar Müller, Claire Myerson, Silvia P. Neciosup, Birgitte Vrou Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault‐Llorca, Aleix Prat, Hope S. Rugo, Elżbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer - The Breast 2024 cited by 197

  21. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

    Authors: Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, Shusen Wang, Noelia Martínez-Jáñez, Giuliano Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M. Fairhurst, Sabrina S. Khan, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli, for the TROPION-Breast01 Investigators, Betiana Romitelli, Ernesto Korbenfeld, Cristian Buono, Arturo Barbero, Geronimo Rosselli, Sergio Daniele, Sandra Anabel Ostoich, Hans Wildiers, Kevin Punie, Joëlle Collignon, Guy Jérusalem, Andrea Gombos, Giuliano Borges, Pedro Emanuel Rubini Liedke, Marcelle Goldner Cesca, Patrícia Medeiros Milhomem Beato, Laura Testa, Hélio Pinczowski, Liane Rapatoni, Debora de Melo Gagliato Jardim, José Bines, David W. Cescon, Jamil Asselah, Andre Blais, Joanne Yu, Jennifer Friedmann, Cristiano Ferrario, Binghe Xu, Shusen Wang, Qingyuan Zhang, ZeFei Jiang, Zhongsheng Tong, Quchang Ouyang, Jingfen Wang, Tingjing Yao, Yongsheng Wang, Xiaojia Wang, Meili Sun, Hui Li, Shu Wang, Yuan Sheng, Aimin Zang, Zhang Zhanmin, Wenyan Chen, Xian Wang, Zhong Ouyang, Wěi Li, Barbara Pistilli, Thomas Bachelot, Mony Ung, Cristian Villanueva, Delphine Garbay, Anne-Claire Hardy-Bessard, Audrey Mailliez, Stéphanie Bécourt, William Mina, Thomas Decker, Julia Radosa, Andreas Schneeweiß, Michael Braun, Bahriye Aktas, Gábor Rubovszky, Zsuzsanna Pápai, Tibor Csőszi, Yousuf Al-Farhat, Ankit Patel, Vineet Govinda Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sen Sharma, Rajani Priya Yedla, Michelino De Laurentiis, Ida Paris and 101 more - Journal of Clinical Oncology 2024 cited by 140

  22. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, A. Allen, PierFranco Conte - European Journal of Cancer 2023 cited by 111

  23. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

    Authors: Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock‐Ah Im, Denise A. Yardley, Michael Untch, Chiun‐Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca Moroose, Sherene Loi, F. Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobágyi - Therapeutic Advances in Medical Oncology 2023 cited by 99

  24. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wěi Li, Quchang Ouyang, Xichun Hu, Ying Cheng, Min Yan, Yueyin Pan, Yuee Teng, Xi Yan, Ying Wang, Weimin Xie, Xiaohua Zeng, Xiaojia Wang, Chang-Lu Hu, Cuizhi Geng, Hongwei Zhang, Wenxin Li, Xinhong Wu, Jincai Zhong, Jingwei Xu, Yanxia Shi, Wenhua Wei, Nayima Bayaxi, Xiaoyu Zhu, Binghe Xu - The Lancet Oncology 2023 cited by 95